Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in MDS/AML

Peter Truong, Sylvie Shen, Swapna Joshi, Md Imtiazul Islam, L. Zhong, Mark J. Raftery, Ali Afrasiabi, Hamid Alinejad‐Rokny, Mary Nguyen, Xiaoheng Zou, Golam Sarower Bhuyan, Chowdhury H. Sarowar, Elaheh Sadat Ghodousi, Olivia Stonehouse, Sara Mohamed, Cara E. Toscan, Patrick Connerty, Purvi M. Kakadia, Stefan K. Bohlander, Katharine A. Michie, Jonas Larsson, Richard B. Lock, Carl R. Walkley, Julie A.i. Thoms, Christopher J. Jolly, John E. PimandabioRxiv 2024 · DOI

TL;DR

This study identifies a novel therapeutic strategy for treating Myelodysplastic Neoplasms (MDS) and Acute Myeloid Leukemia (AML) by combining hypomethylating agents (HMAs) with the inhibition of a protein called TOPORS. This combination enhances the effectiveness of HMAs and shows promise for overcoming treatment resistance, while sparing healthy blood cells.

What Problem Does This Paper Address?

Hypomethylating agents (HMAs) like azacitidine (AZA) and decitabine (DAC) are standard treatments for MDS and AML, helping to control the disease and delay its progression. However, a major challenge is that many patients develop resistance to these drugs, leading to treatment failure and relapse. Understanding the mechanisms behind this resistance and finding ways to overcome it is crucial for improving patient outcomes. This paper aims to identify new therapeutic targets that can synergize with HMAs to enhance their efficacy and overcome resistance.

Methods

The researchers employed a genome-wide CRISPR-Cas9 dropout screen in a human MDS-derived cell line (MDS-L) to identify genes whose loss of function sensitizes cells to HMAs. This high-throughput screening method allows for the unbiased identification of genetic vulnerabilities. They then used lentiviral transduction to deliver specific gene edits (sgRNAs) and shRNAs to validate candidate genes. Cellular proliferation assays, colony-forming assays, and xenograft models in mice were used to assess the functional impact of these genetic modifications and drug combinations. Multi-omic approaches, including RNA sequencing and mass spectrometry-based proteomics, were utilized to investigate the molecular mechanisms underlying the observed synergy. Flow cytometry was used to analyze DNA damage response (yH2AX levels), cell cycle progression, and apoptosis.

Datasets

  • Human MDS-L cell line: Used for the genome-wide CRISPR-Cas9 screen and subsequent validation experiments.
  • Human AML cell lines (MOLM-13, TF-1, Kasumi-1): Used to test the broader applicability of the findings.
  • Patient-derived xenograft (PDX) lines (AML-5, AML-16): Used for in vivo validation in mouse models.
  • Publicly available TCGA database: Used to assess TOPORS expression levels in human leukemias.
  • CRISPR dropout screen data: Deposited at GEO under accession #GSE261339.
  • RNA sequencing data: Deposited at GEO under accession #GSE261339.
  • Mass spectrometry proteomics data: Deposited to the ProteomeXchange Consortium with the dataset identifier PXD050539.

Key Insights and Ideas

  • TOPORS as a key vulnerability: The screen identified TOPORS, an E3 ubiquitin and SUMO ligase, as a critical gene whose loss significantly sensitizes leukemia cells to HMAs. This was a surprising finding, as TOPORS' role in this context wasn't previously well-understood.
  • Impaired DNA Damage Response (DDR): Loss of TOPORS leads to a defective DNA damage response in leukemia cells treated with HMAs. This means that the DNA damage caused by HMAs persists, ultimately leading to cell death.
  • SUMOylation blockade as a surrogate: Since direct inhibitors of TOPORS are not readily available, the study demonstrated that inhibiting protein SUMOylation more broadly (upstream of TOPORS) using TAK-981 can mimic the effects of TOPORS loss, suggesting a viable therapeutic strategy.
  • DNMT1-dependent mechanism: The synergy appears to be specifically linked to the accumulation of DNA-DNMT1 adducts, which are formed by HMAs. TOPORS deficiency hinders the resolution of these adducts, leading to increased cytotoxicity.
  • Sparing healthy hematopoiesis: A critical finding is that the combination therapy, both in vitro and in vivo, effectively targets leukemic cells while largely sparing healthy hematopoietic stem and progenitor cells. This is crucial for developing safe and effective treatments.

Key Results

  • A genome-wide CRISPR-Cas9 screen identified TOPORS as a top loss-of-function target that sensitizes MDS-L cells to azacitidine (AZA).
  • Depletion of TOPORS led to hypersensitivity to HMAs (up to 3.4-fold increase in sensitivity to AZA) in MDS-L cells and various AML cell lines.
  • TOPORS-edited cells showed increased accumulation of yH2AX (a marker of DNA breaks) and delayed cell cycle progression upon AZA treatment, indicating an impaired DNA damage response.
  • In xenograft models, TOPORS-edited MOLM-13 cells showed significantly reduced leukemia burden and delayed disease progression when treated with AZA.
  • Inhibition of SUMOylation with TAK-981 synergized with HMAs in both cell lines and in vivo models, partially recapitulating the effects of TOPORS loss.
  • The combination of HMAs with TAK-981 did not impair healthy hematopoiesis in vitro or in vivo.
  • The synergy was found to be DNMT1-dependent, as inhibiting DNMT1 directly with GSK3685032 also sensitized cells to HMAs.

Limitations and Future Work

  • Lack of direct TOPORS inhibitors: The study highlights the absence of specific pharmacological inhibitors for TOPORS, necessitating the use of SUMOylation inhibitors like TAK-981 as a surrogate. Future work could focus on developing direct TOPORS inhibitors.
  • Inflammatory pathways: While HMAs can induce anti-tumor inflammatory responses in solid tumors, this mechanism was not found to be enriched in the MDS/AML cells studied. The authors suggest further investigation into whether these pathways play a role in HMA response in other contexts or in a non-proliferative manner.
  • Redundancy in DNA-DNMT1 adduct clearance: The study suggests that while TOPORS plays a role, there might be redundant pathways (e.g., involving RNF4) for clearing DNA-DNMT1 adducts, particularly in healthy cells. This redundancy might explain why healthy cells are spared. Further research could explore these redundant pathways.
  • Splicing modulators: The authors speculate that targeting TOPORS might lead to similar deficits in DDR proteins via mis-splicing, similar to findings with splicing modulators. They suggest it would be worthwhile to investigate combining HMAs with splicing modulators for therapeutic benefit.

Summary updated

Abstract

ABSTRACT Hypomethylating agents (HMAs) are frontline therapies effective at altering the natural course of Myelodysplastic Neoplasms (MDS) and Acute Myeloid Leukemia (AML). However, acquired resistance and treatment failure are hallmarks of HMA therapy. To address this clinical need, we performed a genome-wide CRISPR-Cas9 screen in a human MDS-derived cell line, MDS-L, and identified TOPORS as a highly ranked loss-of-function target that synergizes with HMAs, reducing leukemic burden and improving survival in xenograft models. We demonstrate that the depletion of TOPORS mediates sensitivity to HMAs by predisposing leukemic blasts to an impaired DNA damage response (DDR) accompanied by an accumulation of SUMOylated DNMT1 in HMA-treated TOPORS-depleted cells. Importantly, the combination of HMAs with targeting of TOPORS did not functionally impair healthy hematopoiesis. While inhibitors of TOPORS are currently unavailable, we show that inhibition of protein SUMOylation (upstream of TOPORS functions) with TAK-981 partially phenocopies HMA-sensitivity and DDR impairment. Overall, our data suggest that the combination of HMAs with the inhibition of SUMOylation or TOPORS demonstrates a favourable therapeutic index and is a rational treatment framework for High-Risk MDS (HR-MDS) or AML.
BibTeX
@misc{truong2024genome,
  author = {Peter Truong and Sylvie Shen and Swapna Joshi and Md Imtiazul Islam and L. Zhong and Mark J. Raftery and Ali Afrasiabi and Hamid Alinejad‐Rokny and Mary Nguyen and Xiaoheng Zou and Golam Sarower Bhuyan and Chowdhury H. Sarowar and Elaheh Sadat Ghodousi and Olivia Stonehouse and Sara Mohamed and Cara E. Toscan and Patrick Connerty and Purvi M. Kakadia and Stefan K. Bohlander and Katharine A. Michie and Jonas Larsson and Richard B. Lock and Carl R. Walkley and Julie A.I. Thoms and Christopher J. Jolly and John E. Pimanda and John E. Pimanda},
  title = {{Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in MDS/AML}},
  year = {2024},
  doi = {10.1101/2024.04.17.589858},
  howpublished = {bioRxiv},
}
Figure